On the subject in the title: Semaglutide in people without diabetes: what the evidence base looks like Working notes rather than a conclusion.
Two things I would like separated before anyone answers on Semaglutide in people without diabetes, because they get bundled and then argued about as one thing.
The first is descriptive: what has actually been observed, by whom, and how. The second is causal: why. I am asking about the first only.
Narrowing the opening post, because the general version has more than one answer.
Approved indications differ by jurisdiction and change. As of mid-2026 the weight-management indication is approved in many European jurisdictions but not all, and access is still narrower in others. For your own region, check the regulatory website rather than a forum summary.
I have changed my mind on this once already, so take it as current rather than settled.
Everything in the opening post holds. The case it does not cover is the one I have.
On dose steps: the four-week interval in the pivotal programme was a trial design choice, and slower escalation was not studied. That means the evidence supports not going faster and says nothing at all about going slower.
Staff rationale: Hidden by community flags. Described a research-use-only compound as approved for human use after a correction earlier in this topic (R4).
Solutions of semaglutide can look faintly opalescent without anything being wrong. Visible particulate, fibres or frank cloudiness are a different observation entirely and are worth raising with the supplier rather than reasoning about.
I looked this up rather than remembered it, which is the right order.
The corresponding entry is in the public moderation log. Hidden posts are never deleted.
The 2.4 mg maintenance dose in the weight-management programme and the 1.0 mg diabetes dose are frequently discussed as though they were the same drug at different strengths. They are, but the trials behind them enrolled different populations for different endpoints, so the evidence does not transfer sideways.
That is what I would do. It may not be what is correct.
The arithmetic in post #6 is right; the assumption feeding it is the part to check.
Nausea is dose-related and adaptation-related, and both are true at once. The pattern most people describe is a return of symptoms at each escalation followed by adaptation, rather than a single course of adaptation at the start.
Semaglutide in people without diabetes is well covered in the tag pages, and the older discussions are better than the recent ones because they were argued out properly. Worth twenty minutes before adding to this one.
Picking up post #6: that is the part I would want checked first.
Research-use-only semaglutide is not a licensed medicine, is not manufactured to pharmaceutical standards, and is not approved for human use. That is a statement about what it is, not a coded opinion about anything.
Take the reasoning and check the arithmetic; I do not always get it right.
On post #8 — agreed on the reasoning, with one qualification.
Semaglutide's structure is a modified backbone with a C18 diacid attached through a spacer. The acylation is the reason for the long half-life and it is also the reason a plain sequence comparison against native GLP-1 is misleading about how the molecule behaves.
The honest answer is that it depends, and here is what it depends on.
Injection site does not appear to matter much for semaglutide exposure. The published comparisons of abdomen, thigh and upper arm found differences small enough to be clinically unimportant, which is not true of every injectable.
Flagging that the sources on this are thinner than the confidence in the thread suggests.
Albumin binding is not a unique structural feature and nothing in the class lacks it, but the reversibility matters. Semaglutide binds albumin covalently through a fatty side chain, which creates a very long half-life at the cost of sequestering the free form. That is a trade-off and it is the trade-off that allows weekly dosing.
Renal outcomes moved this compound out of the metabolic-only conversation. FLOW reported on kidney endpoints in people with type 2 diabetes and chronic kidney disease, which is a narrower population than the discussion here usually assumes.
Post #11 is right about the mechanism and I think understates the practical bit.
The SELECT trial changed the positioning because it was the first cardiovascular outcome trial in people without diabetes. That decoupled the cardiovascular argument from glycaemic control, which is why it mattered beyond its own numbers.
Genuinely open to being wrong about this one.
Post #11 and I disagree about the size of the effect, not about the direction.
On identity confirmation: a mass close to 4113.6 Da on the intact molecule is consistent with semaglutide and is also consistent with several closely related species. Mass narrows the field; it does not close it, and no certificate should be read as though it did.
I am confident about the direction and much less about the magnitude.
Semaglutide versus liraglutide in STEP 8: semaglutide produced greater weight reduction and the discontinuation rates differed. But the trial was open-label for the dosing schedule, which admits expectation effects. Weekly versus daily itself is part of the comparison, not a confounding variable to be removed.
Caveat: everything above assumes the paperwork is what it says it is.
Cardiovascular data in people without diabetes is the specific contribution of SELECT, and it is worth being precise that the enrolled population had established cardiovascular disease. That is not the same as the general population and the result should not be quoted as though it were.
Nothing to add on the substance. Thank you for taking the question at face value.
Adding the measurement that post #19 says would settle it.
The opalescent appearance in semaglutide solutions is occasionally noted and the mechanism is unclear. It does not appear to correlate with product failure in practice. Visible particles or frank cloudiness is different and would be reason to contact the supplier.
It took me longer than it should have to see that.
The arithmetic in post #20 is right; the assumption feeding it is the part to check.
On alcohol: the labelling does not contraindicate it, but it raises gastric irritation risk and semaglutide already does that. There is no published interaction study and the conservative position is to limit it if you are titrating or if gastrointestinal symptoms are troublesome.
Speaking for myself and not for anyone else who has posted here.
The C-cell question: semaglutide triggered medullary thyroid carcinoma in rodent toxicology studies. A signal in rodents does not automatically appear in humans, but it is the reason the compound is contraindicated in people with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2.
Written in the hope of being told what I have missed.
Is there a ceiling dose beyond which the effect plateaus? The trials did not study that because they stopped at 2.4 mg. Some people report trying higher doses, but trial data is absent and off-label dosing enters territory this site does not advise on.
I am reporting what happened, not recommending it.
Narrowing post #24, because the general version has more than one answer.
On the injection-day question: the labelling for licensed semaglutide allows the day to be changed provided at least two days separate the two injections. That interval is not arbitrary — it is what stops two doses stacking inside one absorption window.
Cardiovascular data in people without diabetes is the specific contribution of SELECT, and it is worth being precise that the enrolled population had established cardiovascular disease. That is not the same as the general population and the result should not be quoted as though it were.
Where the Semaglutide in people without diabetes reasoning breaks down for me is the step from the group result to the individual case. That step is almost never argued for.
Post #26 and I disagree about the size of the effect, not about the direction.
On dose steps: the four-week interval in the pivotal programme was a trial design choice, and slower escalation was not studied. That means the evidence supports not going faster and says nothing at all about going slower.
I would want the raw data before agreeing with my own summary of it.
Useful. I had the fact and not the reason, which turns out to be the important half.
Solutions of semaglutide can look faintly opalescent without anything being wrong. Visible particulate, fibres or frank cloudiness are a different observation entirely and are worth raising with the supplier rather than reasoning about.
That is where I would start, not where I would stop.